Drug response prediction in high-risk multiple myeloma

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Drug response prediction in high-risk multiple myeloma. / Vangsted, A. J.; Helm-Petersen, S.; Cowland, J. B.; Jensen, P. B.; Gimsing, P.; Barlogie, B.; Knudsen, S.

In: Gene, Vol. 644, 2018, p. 80-86.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Vangsted, AJ, Helm-Petersen, S, Cowland, JB, Jensen, PB, Gimsing, P, Barlogie, B & Knudsen, S 2018, 'Drug response prediction in high-risk multiple myeloma', Gene, vol. 644, pp. 80-86. https://doi.org/10.1016/j.gene.2017.10.071

APA

Vangsted, A. J., Helm-Petersen, S., Cowland, J. B., Jensen, P. B., Gimsing, P., Barlogie, B., & Knudsen, S. (2018). Drug response prediction in high-risk multiple myeloma. Gene, 644, 80-86. https://doi.org/10.1016/j.gene.2017.10.071

Vancouver

Vangsted AJ, Helm-Petersen S, Cowland JB, Jensen PB, Gimsing P, Barlogie B et al. Drug response prediction in high-risk multiple myeloma. Gene. 2018;644:80-86. https://doi.org/10.1016/j.gene.2017.10.071

Author

Vangsted, A. J. ; Helm-Petersen, S. ; Cowland, J. B. ; Jensen, P. B. ; Gimsing, P. ; Barlogie, B. ; Knudsen, S. / Drug response prediction in high-risk multiple myeloma. In: Gene. 2018 ; Vol. 644. pp. 80-86.

Bibtex

@article{bcf7494bbcc04a21b289397635992281,
title = "Drug response prediction in high-risk multiple myeloma",
abstract = "A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.",
keywords = "Drug response prediction, High-risk, Multiple myeloma",
author = "Vangsted, {A. J.} and S. Helm-Petersen and Cowland, {J. B.} and Jensen, {P. B.} and P. Gimsing and B. Barlogie and S. Knudsen",
year = "2018",
doi = "10.1016/j.gene.2017.10.071",
language = "English",
volume = "644",
pages = "80--86",
journal = "Gene",
issn = "0378-1119",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Drug response prediction in high-risk multiple myeloma

AU - Vangsted, A. J.

AU - Helm-Petersen, S.

AU - Cowland, J. B.

AU - Jensen, P. B.

AU - Gimsing, P.

AU - Barlogie, B.

AU - Knudsen, S.

PY - 2018

Y1 - 2018

N2 - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

AB - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2–4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2–27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

KW - Drug response prediction

KW - High-risk

KW - Multiple myeloma

U2 - 10.1016/j.gene.2017.10.071

DO - 10.1016/j.gene.2017.10.071

M3 - Journal article

C2 - 29122646

AN - SCOPUS:85034446843

VL - 644

SP - 80

EP - 86

JO - Gene

JF - Gene

SN - 0378-1119

ER -

ID: 214462561